title: Direct comparison of dietary portfolio vs statin on C-reactive protein.
abstract: BACKGROUND
  3-Hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) markedly reduce serum cholesterol and have anti-inflammatory effects. The effect of cholesterol-lowering diets on inflammatory biomarkers is less well known.
  
  
  OBJECTIVE
  To compare the efficacy of a dietary combination (portfolio) of cholesterol-lowering foods vs a statin in reducing C-reactive protein (CRP) as a biomarker of inflammation linked to increased cardiovascular disease risk.
  
  
  METHODS
  In all, 34 hyperlipidemic subjects completed three 1-month treatments as outpatients in random order: a very low-saturated fat diet (control); the same diet with 20 mg lovastatin (statin); and a diet high in plant sterols (1.0 g/1000 kcal), soy protein (21.4 g/1000 kcal), viscous fibers (9.8 g/1000 kcal), and almonds (14 g/1000 kcal) (portfolio). Fasting blood samples were obtained at weeks 0, 2, and 4.
  
  
  RESULTS
  Using the complete data, no treatment reduced serum CRP. However, when subjects with CRP levels above the 75th percentile for previously reported studies (> 3.5 mg/l) were excluded, CRP was reduced similarly on both statin, -16.3 +/- 6.7% (n = 23, P = 0.013) and dietary portfolio, -23.8 +/- 6.9% (n = 25, P = 0.001) but not the control, 15.3 +/- 13.6% (n = 28, P = 0.907). The percentage CRP change from baseline on the portfolio treatment (n = 25) was greater than the control (n = 28, P = 0.004) but similar to statin treatment (n = 23, P = 0.349). Both statin and portfolio treatments were similar in reducing CRP and numerically more effective than control but only the change in portfolio was significant after the Bonferroni adjustment.
  
  
  CONCLUSIONS
  A combination of cholesterol-lowering foods reduced C-reactive protein to a similar extent as the starting dose of a first-generation statin.
authors.affiliation: Clinical Nutrition and Risk Factor Modification Center, St Michael's Hospital, Toronto, Ontario, Canada.
authors.forename: D J A
authors.initials: DJ
authors.lastname: Jenkins
authors.forename: C W C
authors.initials: CW
authors.lastname: Kendall
authors.forename: A
authors.initials: A
authors.lastname: Marchie
authors.forename: D A
authors.initials: DA
authors.lastname: Faulkner
authors.forename: A R
authors.initials: AR
authors.lastname: Josse
authors.forename: J M W
authors.initials: JM
authors.lastname: Wong
authors.forename: R
authors.initials: R
authors.lastname: de Souza
authors.forename: A
authors.initials: A
authors.lastname: Emam
authors.forename: T L
authors.initials: TL
authors.lastname: Parker
authors.forename: T J
authors.initials: TJ
authors.lastname: Li
authors.forename: R G
authors.initials: RG
authors.lastname: Josse
authors.forename: L A
authors.initials: LA
authors.lastname: Leiter
authors.forename: W
authors.initials: W
authors.lastname: Singer
authors.forename: P W
authors.initials: PW
authors.lastname: Connelly
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000187:drug effects* / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000097:blood / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood*; D018752:Diet, Fat-Restricted; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D006949:Hyperlipidemias / Q000097:blood* / Q000178:diet therapy / Q000188:drug therapy; D007249:Inflammation / Q000097:blood; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
chemical_list: D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002097:C-Reactive Protein; D002784:Cholesterol